BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 29773599)

  • 1. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
    Horiguchi H; Kobune M; Kikuchi S; Yoshida M; Murata M; Murase K; Iyama S; Takada K; Sato T; Ono K; Hashimoto A; Tatekoshi A; Kamihara Y; Kawano Y; Miyanishi K; Sawada N; Kato J
    Haematologica; 2016 Apr; 101(4):437-47. PubMed ID: 26802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
    Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS
    Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway.
    Pavlaki K; Pontikoglou CG; Demetriadou A; Batsali AK; Damianaki A; Simantirakis E; Kontakis M; Galanopoulos A; Kotsianidis I; Kastrinaki MC; Papadaki HA
    Stem Cells Dev; 2014 Jul; 23(14):1568-81. PubMed ID: 24617415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
    Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
    Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Khandanpour C; Cadeddu RP; Gutekunst J; Wilk CM; Fenk R; Zilkens C; Hermsen D; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Leukemia; 2016 Mar; 30(3):683-91. PubMed ID: 26601782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.
    Fei C; Zhao Y; Guo J; Gu S; Li X; Chang C
    Eur J Haematol; 2014 Dec; 93(6):476-86. PubMed ID: 24889123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes.
    Lubkova ON; Tzvetaeva NV; Momotyuk KS; Belkin VM; Manakova TE
    Bull Exp Biol Med; 2011 May; 151(1):13-5. PubMed ID: 22442792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
    Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
    Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
    Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
    [No Abstract]   [Full Text] [Related]  

  • 17. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.
    Geyh S; Oz S; Cadeddu RP; Fröbel J; Brückner B; Kündgen A; Fenk R; Bruns I; Zilkens C; Hermsen D; Gattermann N; Kobbe G; Germing U; Lyko F; Haas R; Schroeder T
    Leukemia; 2013 Sep; 27(9):1841-51. PubMed ID: 23797473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-β boosts the functionality of human bone marrow-derived mesenchymal stromal cells.
    Kale VP
    Cell Biol Int; 2020 Nov; 44(11):2293-2306. PubMed ID: 32749730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway.
    Yuan B; El Dana F; Ly S; Yan Y; Ruvolo V; Shpall EJ; Konopleva M; Andreeff M; Battula VL
    PLoS One; 2020; 15(11):e0242809. PubMed ID: 33253299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.